FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313893199> ?p ?o ?g. }

• W4313893199 endingPage "308" @default.
• W4313893199 startingPage "256" @default.
• W4313893199 abstract "We read with great interest that several studies reported the co- and secondary bacterial infections following severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) infection, especially for patients with severe-to-critical coronavirus disease 2019 (COVID-19).1Youngs J. Wyncoll D. Hopkins P. Arnold A. Ball J. Bicanic T. Improving antibiotic stewardship in COVID-19: bacterial co-infection is less common than with influenza.J Infect. 2020; 81 (-e7): e55Abstract Full Text Full Text PDF PubMed Scopus (37) Google Scholar, 2Lansbury L. Lim B. Baskaran V. Lim W.S. Co-infections in people with COVID-19: a systematic review and meta-analysis.J Infect. 2020; 81: 266-275Abstract Full Text Full Text PDF PubMed Scopus (698) Google Scholar, 3Murgia F. Fiamma M. Serra S. Olla S. Garau M.C. Cocco E. et al.The impact of secondary infections in COVID-19 critically ill patients.J Infect. 2022; 84 (-e7): e116Abstract Full Text Full Text PDF PubMed Scopus (3) Google Scholar However, the reported incidences of secondary infection post COVID-19 were inconsistent in different studies.4Musuuza J.S. Watson L. Parmasad V. Putman-Buehler N. Christensen L. Safdar N. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and meta-analysis.PLoS One. 2021; 16e0251170Crossref PubMed Scopus (154) Google Scholar,5Lai C.C. Wang C.Y. Hsueh P.R. Co-infections among patients with COVID-19: the need for combination therapy with non-anti-SARS-CoV-2 agents?.J Microbiol Immunol Infect. 2020; 53: 505-512Crossref PubMed Scopus (252) Google Scholar Therefore, continuing surveillance investigation of the pathogens, especially multidrug-resistant organisms causing secondary infections following COVID-19 is needed to provide the epidemiologic information and further guide the appropriate use of antimicrobials for the patients with SARS-CoV-2 infection.6Lai C.C. Yu W.L. Appropriate use of antimicrobial therapy for COVID-19 co-infection.Immunotherapy. 2021; 13: 1067-1070Crossref PubMed Scopus (1) Google Scholar Although it is well known that Streptococcus pneumoniae and Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA) could be the common pathogens causing secondary infection following influenza,7Klein E.Y. Monteforte B. Gupta A. Jiang W. May L. Hsieh Y.H. et al.The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis.Influenza Other Respir Viruses. 2016; 10: 394-403Crossref PubMed Scopus (269) Google Scholar it is unclear whether the incidence of MRSA secondary infection in patients with COVID-19 could be as high as that in patients with influenza. We, therefore, examined a large dataset of global healthcare records to determine the incidence of MRSA infection within one month after COVID-19 infection, and compare these risks with the matched patients following infection with influenza. This retrospective cohort study was conducted using the TriNetX health records network with 73 healthcare organizations worldwide. COVID-19 was defined by the ICD-10 codes (U07.1-U07.2, B97.29, B34.2, J12.81) or positive laboratory results (TNX:LAB:9008-SARS coronavirus 2 and related RNA), and influenza was defined by ICD-10 codes (J09-J11). Cases who were 18 or older were included between March 1, 2020 and September 30, 2022. To avoid contamination between cohorts, the control influenza cohort excluded cases who had COVID-19 within 3 months, and the influenza cases were excluded in the COVID-19 cohort at any point in time. Primary outcome was the risk of secondary MRSA infection (B95.62, A49.02, J15.212) after the 48 h of the index event. Secondary outcome was the risk of MRSA bacteremia (R78.81). Propensity score with 1:1 matching method was used to identify matched cohorts. Any characteristic with a standardized mean difference between cohorts lower than 0.1 was considered well matched. Hazard ratios (HRs) with 95% confidence intervals were calculated using the Cox model and the null hypothesis of no difference between cohorts was tested using log-rank tests. The Kaplan-Meier estimator was used to estimate the incidence of the outcomes. Initial, 3,004,268 patients with COVID-19 and 128,393 patients with influenza were identified and then, each 128,392 cases remained in the both cohorts after propensity score matching (Table 1). Compared with the influenza cohort, the COVID-19 cohort was associated with the higher risk of secondary MRSA infection (HR, 1.52; 95% CI, 1.19-1.94) within one month. The higher risk of MRSA infection following SARS-CoV-2 infection than influenza cohort remained unchanged in different time frames (2-5 days: HR, 1.78; 95% CI, 1.20-2.64; 2-10 days: HR, 1.63; 95% CI, 1.90-2.24; 2-15 days: HR, 1.65; 95% CI, 1.24-2.20; 2-20 days: HR, 1.56; 95% CI, 1.20-2.04 and 2-30 days: HR, 1.52; 95% CI, 1.19-1.94). In addition, COVID-19 patients also had higher risk of MRSA bacteremia than patients with influenza in one month (HR, 1.43; 95% CI, 1.16-1.75). The higher risk of MRSA bacteremia remained consistent across different time periods (2-5 days: HR, 1.30; 95% CI, 0.94-1.79; 2-10 days: HR, 1.46; 95% CI, 1.12-1.91; 2-15 days: HR, 1.49; 95% CI, 1.18-1.90; 2-20 days: HR, 1.55; 95% CI, 1.24-1.93 and 2-30 days: HR, 1.43; 95% CI, 1.16-1.75). Further Kaplan-Meier estimation showed a similar finding that the incidence of MRSA infection for COVID-19 patients was higher than those with influenza (Log rank p < 0.05) (Fig. 1).Table 1Baseline characteristics for COVID-19 and influenza cohorts before and after matching.Before matchingAfter matchingCOVID-19InfluenzaSMDCOVID-19InfluenzaSMDNumber3,004,268128,393128,392128,392Age; mean ± SD, year47.3±17.747.5±19.30.78147.4±19.247.5±19.30.004Sex; n (%)Female1,678,280 (55.9)75,617 (58.9)0.06175,641 (58.9%)75,616 (58.9%)<0.001Male1,288,549 (42.9)51,780 (40.3)0.05251,763 (40.3%)51,780 (40.3%)<0.001Race; n (%)White1,603,957 (53.3)488,603 (60.3)0.14184,667 (65.9%)83,796 (65.3%)0.014Black or African American402,873 (13.4)17,012 (13.2)0.00517,005 (13.2)17,012 (13.2)<0.001Hispanic or Latino234,190 (7.8)9,562 (7.4)0.0139,280 (7.2)9,562 (7.4)0.008Comorbidities; n (%)Disease of respiratory system852,444 (28.4)66,991 (52.2)0.50066,952 (52.1)66,990 (52.2)0.001Disease of circulatory system829,730 (27.6)59,017 (46.0)0.38858,991 (45.9)59,016 (46.0)<0.001Hypertensive disease623,360 (20.7)44,753 (34.9)0.31944,906 (35.0)44,752 (34.9)0.003Neoplasms409,135 (13.6)35,981 (28.0)0.36135,558 (27.7)35,980 (28.0)0.007Chronic lower respiratory disease313,002 (10.4)26,912 (21.0)0.25126,470 (20.6)26,912 (21.0)0.008Diabetes mellitus301,326 (10.0)24,521 (19.1)0.25924,308 (18.9)24,520 (19.1)0.004Asthma194,640 (6.5)16,751 (13.0)0.22316,425 (12.8)16,751 (13.0)0.008Chronic kidney disease150,798 (5.0)16,864 (13.1)0.28516,659 (13.0)16,863 (13.1)0.005Overweight, obesity and other hyperalimentation358,122 (11.9)23,370 (18.2)0.17623,096 (18.0)23,370 (18.2)0.006SD, standard deviation; SMD, Standardized mean difference Open table in a new tab SD, standard deviation; SMD, Standardized mean difference In summary, this retrospective cohort study demonstrated that COVID-19 patients would carry a significantly higher risk of MRSA infections, including MRSA bacteremia, than patients with influenza. The causes of higher risk of MRSA infection and bacteremia in COVID-19 patients than patients with influenza could be multifactorial. In contrast to influenza, systematic corticosteroid and interleukin-6 blockade are recommended for hospitalized patients with severe COVID-19. However, the use of these anti-inflammatory agents may increase the risk of secondary infection. In addition, infection prevention and control measures may not be strictly executed during COVID-19 pandemic. Thus, the incidence of nosocomial infections including MRSA infection could be higher than usual. Finally, the immune status following SARS-CoV-2 infection could be different from those after influenza. However, further investigation is warranted to clarify these mechanisms and validate our findings. Overall, the finding of the present study is consistent with several observational studies which reported that MRSA could be a frequent pathogen causing superinfection following SARS-CoV-2 infections.8Habib G. Mahmood K. Gul H. Tariq M. Ain Q.U. Hayat A. et al.Pathophysiology of methicillin-resistant Staphylococcus aureus superinfection in COVID-19 patients.Pathophysiology. 2022; 29: 405-413Crossref PubMed Scopus (1) Google Scholar,9Weidmann M.D. Berry G.J. Zucker J.E. Huang S. Sobieszczyk M.E. Green D.A. Bacterial pneumonia and respiratory culture utilization among hospitalized patients with and without COVID-19 in a New York city hospital.J Clin Microbiol. 2022; 60e0017422Crossref PubMed Scopus (0) Google Scholar In one review on the epidemiology of MRSA lung infection in patients with COVID-19,10Bassetti M. Magnasco L. Vena A. Portunato F. Giacobbe D.R. Methicillin-resistant Staphylococcus aureus lung infection in coronavirus disease 2019: how common?.Curr Opin Infect Dis. 2022; 35: 149-162Crossref PubMed Scopus (4) Google Scholar the relative prevalence among all identified bacteria could range from 2% to 29%. All these findings indicated the critical role of MRSA among patients with COVID-19 and suggestd that clinicians keep alert the possible MRSA secondary infection following SARS-CoV-2 infections. Because inappropriate empirical antibiotic would be associated with poor outcome of patient with sepsis, empirical use of anti-MRSA agents for COVID-19 patients with secondary infection should be considered, especially for those with risk of MRSA infection. This study had several limitations. First, although we matched the baseline characteristics of COVID-19 and influenza cohorts using propensity score method, some residual confounding factors, such as the disease severity, the use of anti-inflammatory agents, and the vaccine effect still existed. Second, SARS-CoV-2 infection could present as asymptomatic, so the influenza cohort might include patients without identified COVID-19. To avoid this confounding, the cases in the influenza cohort in this study was identified before 2020, when there was no COVID-19. In conclusion, patients with COVID-19 would be associated with a higher risk of secondary MRSA infection than those with influenza. During this pandemic, clinicians should consider MRSA as potential pathogens causing secondary infection following SARS-CoV-2 infection. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper." @default.
• W4313893199 created "2023-01-10" @default.
• W4313893199 creator A5000528371 @default.
• W4313893199 creator A5021219562 @default.
• W4313893199 creator A5021227488 @default.
• W4313893199 creator A5022398404 @default.
• W4313893199 creator A5058593693 @default.
• W4313893199 creator A5068719939 @default.
• W4313893199 date "2023-03-01" @default.
• W4313893199 modified "2023-10-09" @default.
• W4313893199 title "The risk of methicillin-resistant Staphylococcus aureus infection following COVID-19 and influenza: A retrospective cohort study from the TriNetX network" @default.
• W4313893199 cites W2402456610 @default.
• W4313893199 cites W3026446975 @default.
• W4313893199 cites W3029242200 @default.
• W4313893199 cites W3037059532 @default.
• W4313893199 cites W3157703981 @default.
• W4313893199 cites W3168708533 @default.
• W4313893199 cites W4220681308 @default.
• W4313893199 cites W4220971807 @default.
• W4313893199 cites W4281664902 @default.
• W4313893199 cites W4288450755 @default.
• W4313893199 doi "https://doi.org/10.1016/j.jinf.2023.01.006" @default.
• W4313893199 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36632945" @default.
• W4313893199 hasPublicationYear "2023" @default.
• W4313893199 type Work @default.
• W4313893199 citedByCount "5" @default.
• W4313893199 countsByYear W43138931992023 @default.
• W4313893199 crossrefType "journal-article" @default.
• W4313893199 hasAuthorship W4313893199A5000528371 @default.
• W4313893199 hasAuthorship W4313893199A5021219562 @default.
• W4313893199 hasAuthorship W4313893199A5021227488 @default.
• W4313893199 hasAuthorship W4313893199A5022398404 @default.
• W4313893199 hasAuthorship W4313893199A5058593693 @default.
• W4313893199 hasAuthorship W4313893199A5068719939 @default.
• W4313893199 hasBestOaLocation W43138931991 @default.
• W4313893199 hasConcept C126322002 @default.
• W4313893199 hasConcept C159047783 @default.
• W4313893199 hasConcept C167135981 @default.
• W4313893199 hasConcept C201903717 @default.
• W4313893199 hasConcept C2777052132 @default.
• W4313893199 hasConcept C2779134260 @default.
• W4313893199 hasConcept C2779489039 @default.
• W4313893199 hasConcept C3008058167 @default.
• W4313893199 hasConcept C523546767 @default.
• W4313893199 hasConcept C524204448 @default.
• W4313893199 hasConcept C54355233 @default.
• W4313893199 hasConcept C71924100 @default.
• W4313893199 hasConcept C86803240 @default.
• W4313893199 hasConcept C89423630 @default.
• W4313893199 hasConcept C89623803 @default.
• W4313893199 hasConceptScore W4313893199C126322002 @default.
• W4313893199 hasConceptScore W4313893199C159047783 @default.
• W4313893199 hasConceptScore W4313893199C167135981 @default.
• W4313893199 hasConceptScore W4313893199C201903717 @default.
• W4313893199 hasConceptScore W4313893199C2777052132 @default.
• W4313893199 hasConceptScore W4313893199C2779134260 @default.
• W4313893199 hasConceptScore W4313893199C2779489039 @default.
• W4313893199 hasConceptScore W4313893199C3008058167 @default.
• W4313893199 hasConceptScore W4313893199C523546767 @default.
• W4313893199 hasConceptScore W4313893199C524204448 @default.
• W4313893199 hasConceptScore W4313893199C54355233 @default.
• W4313893199 hasConceptScore W4313893199C71924100 @default.
• W4313893199 hasConceptScore W4313893199C86803240 @default.
• W4313893199 hasConceptScore W4313893199C89423630 @default.
• W4313893199 hasConceptScore W4313893199C89623803 @default.
• W4313893199 hasIssue "3" @default.
• W4313893199 hasLocation W43138931991 @default.
• W4313893199 hasLocation W43138931992 @default.
• W4313893199 hasLocation W43138931993 @default.
• W4313893199 hasOpenAccess W4313893199 @default.
• W4313893199 hasPrimaryLocation W43138931991 @default.
• W4313893199 hasRelatedWork W1798643300 @default.
• W4313893199 hasRelatedWork W1834935829 @default.
• W4313893199 hasRelatedWork W2018382434 @default.
• W4313893199 hasRelatedWork W2067817830 @default.
• W4313893199 hasRelatedWork W2096994712 @default.
• W4313893199 hasRelatedWork W2109861005 @default.
• W4313893199 hasRelatedWork W2326830576 @default.
• W4313893199 hasRelatedWork W2592620649 @default.
• W4313893199 hasRelatedWork W2601429695 @default.
• W4313893199 hasRelatedWork W4382985023 @default.
• W4313893199 hasVolume "86" @default.
• W4313893199 isParatext "false" @default.
• W4313893199 isRetracted "false" @default.
• W4313893199 workType "article" @default.